: AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines

AstraZeneca shares jumped 3% after the Anglo-Swedish drugmaker said it expects its full-year revenues will increase at a higher rate than previously forecast

Previous post Emirates Group posts record half-year profit of $2.7 billion
Next post Kelley Blue Book: The 2024 Acura MDX review: Pricing, tech and more for this poised, midsize luxury SUV